Effectiveness of CAR T-Cell therapy against high risk large B-Cell lymphoma

Researchers at the University of Texas MD Anderson Cancer Center discovered that axi-cel, an autologous anti-CD19 CAR T-cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma, a group in which around half of patients have historically not achieved long-term disease remission with standard chemoimmunotherapy approaches. The ZUMA-12 trial, a Phase 2 open-label, single-arm, multicenter study building on the earlier ZUMA-1 findings, assessed the use of axi-cel as first-line therapy, and interim results showed that 85 percent of patients had an overall response, 74 percent had a complete response, and 70 percent exhibited a continuing response after a median follow-up of 9.3 months. Sattva S. Neelapu, MD, professor of Lymphoma and Myeloma, noted that if successful, CAR T-cell therapy could transform treatment from six months of chemotherapy into a one-time infusion completed within a single month, representing a significant step toward making it a frontline standard of care for aggressive B-cell lymphoma.

One of the notable findings of the ZUMA-12 trial was that the peak level of CAR T cells in the blood and the median CAR T-cell expansion were higher compared to trials where immunotherapy products were generated from patients who had already undergone several lines of chemotherapy, suggesting that earlier treatment preserves greater T-cell fitness and may be linked to stronger therapeutic effectiveness and better patient outcomes. The most common side effects associated with axi-cel treatment included white blood cell count reduction, encephalopathy, anaemia, and cytokine release syndrome, all of which had resolved by the time the data was analysed. Following these promising interim results, researchers plan to continue long-term follow-up with patients, and Neelapu emphasized that a randomized clinical trial will ultimately be required to definitively demonstrate that CAR T-cell therapy is superior to standard chemoimmunotherapy in high-risk patients, while also raising the question of whether the therapy should be explored in intermediate-risk large B-cell lymphoma patients as well.